<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000386197"><TermName>bendamustine hydrochloride</TermName><TermPronunciation>(BEN-duh-MUS-teen HY-droh-KLOR-ide)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat chronic lymphocytic leukemia (CLL). It is also used to treat slow-growing B-cell non-Hodgkin lymphoma (NHL) that has gotten worse within 6 months of treatment with other anticancer drugs. It is being studied in the treatment of other types of cancer. Bendamustine hydrochloride may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite.  Also called Treanda.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713172" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bendamustine hydrochloride&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713171" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;clorhidrato de bendamustina&quot;" language="es" id="_4"/><SpanishTermName>clorhidrato de bendamustina</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar la leucemia linfocítica crónica (LLC). También se usa para tratar el linfoma no Hodgkin (LNH) de células B de crecimiento lento que empeoró dentro de los seis meses de tratamiento con otros medicamentos contra el cáncer. Está en estudio para el tratamiento de otros tipos de cáncer. El clorhidrato de bendamustina puede dañar el ADN de las células cancerosas y destruirlas. Es un tipo de alquilante y un tipo de antimetabolito. También se llama Treanda.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-08-24</DateFirstPublished><DateLastModified>2014-12-10</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000592692">Bendamustine Hydrochloride</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
